Publications

Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.

Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.

See below for some of our recent publications.

Mobile Medical Applications for Substance Use Disorder

Focus of the Report: Substance abuse and drug addiction are conditions that are notoriously difficult to treat with long-term success, as 40% to 60% of patients with drug addiction relapse. Mobile medical applications (MMAs) may fill gaps that currently exist in conventional treatment programs by enabling patients to better manage their care and track their health and wellnes…

CHARGE Syndrome

This report reviews clinical study abstracts and clinical practice guidelines addressing genetic testing for the familial form of CHARGE syndrome.

IpsiHand Upper Extremity Rehabilitation System

The IpsiHand Upper Extremity Rehabilitation System is a brain-computer-interface/robotic arm exoskeleton system for use in chronic stroke patients (≥ 6 months post-stroke) aged ≥ 18 years undergoing stroke rehabilitation, to facilitate muscle re-education and for maintaining or increasing range of motion in the upper extremity.

Peripheral Nerve Field Stimulation for Treatment of Chronic Low Back Pain

Focus of the Report: This report focuses on the use of peripheral nerve field stimulation (PNFS) to treat refractory chronic low back pain (CLBP).

Technology Description: Peripheral nerve field stimulation is a neuromodulation technology characterized by ease of implant with minimized …

Nodify CDT (Biodesix Inc.)

This report evaluates the analytical validity, clinical validity, and clinical utility of the Nodify CDT test.

Breyanzi (Lisocabtagene Maraleucel) for Large B-Cell Lymphoma

Breyanzi (lisocabtagene maraleucel [liso-cel]) is an autologous chimeric antigen receptor (CAR) T-cell therapy, a novel type of immunotherapy in which a patient’s own immune cells are genetically re-programmed to target and attack cancer cells. It is indicated for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after 2 or more lines of …

Prospera (Natera Inc.)

This report evaluates the analytical validity, clinical validity, and clinical utility of the Prospera test.

Oxlumo (Lumasiran) for Primary Hyperoxaluria Type 1

Oxlumo (lumasiran) is a subcutaneously injected, HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. Dosing is weight-based; for children weighing less than 10 kg, the recommended maintenance dose is 3 mg/kg once monthly. Dosing for individua…